Anticipated Release Date: Q3FY24 OR Q4FY24 Multiple Topics TBD—Possible 3 or 4 The goal of the Vaccines Capability Area is to conduct research in order to develop lead candidate vaccines and pretreatments that can be administered Read More
Due: September 18, 2024 FDA approval of a multi-drug autoinjector to reduce logistical burden on the warfighter and increase survivability Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous Read More
Anticipated Release Date: Q1FY24 OR Q2FY24 Small Molecule Therapeutics Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end Read More
Anticipated Release Date: Q3FY24 OR Q4FY24 Multiple Topics TBD—Possible 3 or 4 The goal of the Therapeutics Capability Area is to develop lead candidate medical treatments and pharmaceuticals that, when administered after exposure to a biological Read More
Anticipated Release Date: Q3FY24 Develop a diagnostic prototype strip, compatible with the ChemDx device, able to diagnose opioid exposure. Additional test strips able to differentiate between bacterial vs. viral infection, pre-symptomatic, contagiousness, or disease severity may Read More
Anticipated Release Date: Q2FY25 VaporAgent Demasking –Easily Readable Develop low-burden, low-cost detection capabilities for chemical threat vapors to facilitate doffing PPE as part of the M256A2 modernization effort. Responding to this opportunity requires membership in Read More
Release Date: Q2FY25 Develop novel multi-functional detection indicator technology for vapor and aerosol hazards aimed at decreasing burden via easy-to-use SWaP-C solutions. Responding to this opportunity requires membership in the Countering Weapons of Mass Destruction Consortium. This Read More
Anticipated Release Date: Q4FY24 The SIS program provides the capability to temporarily isolate or quarantine personnel to prevent the spread of infection and safely evacuate patients for transfer off the ship. Capability will be used on Read More
Anticipated Release Date: Q4FY24 The Portable Patient Transport System Enhanced Biodefense (PPTS ENBD) is a patient transport system that enables safe transport of asymptomatic, symptomatic, or infected patients while ensuring that the medical attending personnel and Read More
Anticipated Release Date: Q2FY25 Novel approaches to bioaerosol detection and identification that implement reliable, accurate and timely sampling mechanisms in a diverse range of operational environments. Aim to address current technical challenges such as false positive Read More
NTA is operated by the 501c(3) non-profit Advanced Technology International (ATI). National Technology Alliance (NTA) © 2024 - All rights reserved.